Naturalistic, prospective observational study (n=90) assessing subcutaneous ketamine (0.5 mg/kg initial; clinician-led escalation to 0.75–1.0 mg/kg) for reducing suicide risk and depressive symptoms in patients with depressive episodes, with a healthy control group.
Prospective naturalistic study recruiting 45 patients with a major depressive episode (MDD or bipolar depression) receiving clinician-prescribed subcutaneous ketamine and 45 healthy controls for biomarker and clinical outcome assessment.
Patients receive an initial 0.5 mg/kg SC ketamine protocol (twice weekly for one month) with possible escalation to 0.75 and 1.0 mg/kg and continuation as clinically indicated; outcomes include suicide risk (C-SSRS), depressive symptoms (MADRS), and peripheral biomarkers.
Subcutaneous ketamine for depressive episode; naturalistic dosing with clinician-led escalation.
Subcutaneous (SC) administration; escalation to 0.75 mg/kg and 1.0 mg/kg if inadequate response per clinician.
Assessments and blood collection only
No ketamine; baseline and follow-up assessments and blood sampling (~15 mL).